Overall, as shown in Table 3a, in the multivariate model, baseline risk factors for bacterial pneumonia were older age (HR per 10 years increase in age 1.34; 95% CI 1.14–1.59; P=<0.001), IDU (HR 1.78; 95% CI 1.09–2.90; P=0.02), VL ≥500 HIV-1 RNA copies/mL see more (HR 2.02; 95% CI 1.46–2.81; P=<0.001) and history of recurrent bacterial pneumonia as an ADI (HR 5.38; 95% CI 2.86–10.11; P=<0.001). Asian ethnicity was associated with a decreased risk of bacterial pneumonia (HR 0.17; 95% CI 0.05–0.56; P=0.003). In the multivariate analysis of bacterial pneumonia events in the IL-2 arm, the baseline associations were similar to the overall findings, Asian ethnicity was protective (HR 0.10; 95% CI 0.01–0.74; P=0.02);

being older (HR 1.46; 95% CI 1.15–1.85; P=0.002), having detectable plasma VL (HR 2.27; 95% CI 1.45–3.55; P=<0.001) and having a prior history of recurrent bacterial pneumonia (HR 4.46; 95% CI 1.72–11.54; P=0.002) were associated with increased pneumonia risk. However, IDU was not associated with an increased pneumonia risk (HR 1.46; 95% CI 0.72–2.96; P=0.30). Consistent with the overall findings, in control patients, IDU (HR 2.11; 95% CI 1.06–4.20; P=0.03), recurrent bacterial pneumonia (HR 5.61; 95% CI 2.38–13.24; P≤0.001) and detectable plasma VL (HR 1.85; 95% CI 1.13–3.03; selleck inhibitor P=0.01) were associated with a

significantly increased hazard for pneumonia. In contrast to the overall findings, there was only a trend towards decreased risk with Asian ethnicity (HR 0.27; 95% CI 0.06–1.11; P=0.07) and a trend towards increased risk with older age (HR 1.26; 95% CI 0.99–1.61; P=0.06). As shown in Table 3b, higher proximal VL on study (HR for 1 log10 higher VL 1.28; 95% CI 1.11–1.47; P≤0.001) and receipt of rIL-2 within the last 180 days (HR 1.72; 95% CI 1.12–2.65; P=0.01) were predictors of increased risk for a bacterial pneumonia event; higher proximal CD4 cell count PD184352 (CI-1040) was associated with decreased risk (HR 0.94; 95% CI 0.89–1.00; P=0.04). When adjusted for baseline predictors (age, IDU, ethnicity and history of recurrent bacterial pneumonia) and time-updated CD4 cell count and VL, the hazards for IL-2 patients cycling within 180 days and ≥180 days of a bacterial pneumonia event were 1.66 (95% CI 1.07–2.60; P=0.02) and 0.98 (95% CI 0.70–1.37; P=0.90), respectively, compared with the control arm. In years 1 and 2 in the IL-2 group, the hazard for bacterial pneumonia when rIL-2 cycling was <30, 30–119 and 120–179 days, compared with receipt ≥180 days previously, was 2.59 (95% CI 0.88–7.62; P=0.08), 1.74 (95% CI 0.70–4.30; P=0.23) and 1.21 (95% CI 0.36–4.04; P=0.75), respectively.